SANUWAVE Health, Inc.

For the period ended Dec 31, 2024. Filed Mar 20, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 20, 2025

SNWV$1.88+1.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets as of December 31, 202 and

CONSOLIDATED BALANCE SHEETS

December 31, 2024 and 2023

(In thousands, except share data) · 2024 · 2023
ASSETS
Current Assets:
Cash and cash equivalents		$10,237			$1,797
Accounts receivable, net of allowance of $1,147 and $1,237, respectively	3,329		3,314
Inventory	4,149		2,951
Prepaid expenses and other current assets	682		1,722
Total Current Assets	18,397		9,784
Non-Current Assets:
Property, equipment and right of use assets, net	732		938
Intangible assets, net	3,730		4,434
Goodwill	7,260		7,260
Total Non-Current Assets	11,722		12,632
Total Assets		$30,119			$22,416
LIABILITIES
Current Liabilities:
Senior secured debt		$25,305			$18,278
Convertible promissory notes payable	-		5,404
Convertible promissory notes payable, related parties	-		1,705
Asset-backed secured promissory notes payable	-		3,117
Asset-backed secured promissory notes payable, related parties	-		1,458
Accounts payable	3,728		5,705
Accrued expenses	4,678		5,999
Factoring liabilities	-		1,490
Warrant liability	8,107		14,447
Accrued interest	-		5,444
Accrued interest, related parties	-		669
Current portion of contract liabilities	193		92
Other	334		947
Total Current Liabilities	42,345		64,755
Non-Current Liabilities:
Lease liabilities, less current portion	191		492
Contract liabilities, less current portion	300		347
Total Non-Current Liabilities	491		839
Total Liabilities		$42,836			$65,594
Commitments and Contingencies (Footnote 21)
STOCKHOLDERS’ DEFICIT
Preferred stock, par value $0.001, 5,000,000 shares authorized, 6,175 Series A, 293 Series B, 90 Series C, and 8 Series D designated shares, respectively; no shares issues and outstanding at 2024 and 2023	$	-		$	-
Common stock, par value $0.001, 2,500,000,000 shares authorized, 8,543,686 and 3,041,492 issued and outstanding at 2024 and 2023, respectively *	9		3
Additional paid-in capital	238,685		176,979
Accumulated deficit	(251,421)		(220,049)
Accumulated other comprehensive loss	10		(111)
Total Stockholders’ Deficit	(12,717)		(43,178)
Total Liabilities and Stockholders’ Deficit		$30,119			$22,416

Reflects a one-for-three hundred seventy-five (1:375) reverse stock split of the outstanding shares of the Company's common stock effected on October 18, 2024.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.